Metformin treatment caused cancer stem cell death in pancreatic cancer cell lines

June 19, 2012, American Association for Cancer Research

Results of some preclinical trials have shown that low doses of the antidiabetic drug metformin may effectively destroy cancer stem cells, a group of cells that are considered to be responsible for tumor initiation and, because they are resistant to standard chemotherapies, tumor relapse.

In addition, when was combined with a standard chemotherapy used for , the combination treatment was able to efficiently eradicate both cancer and more differentiated cancer cells, which form the bulk of the tumor, according to data presented by Christopher Heeschen, M.D., Ph.D., at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held in , Nev., from June 18-21, 2012. Heeschen is professor for at the Spanish National Cancer Research Centre in Madrid, Spain.

Most clinical trials of pancreatic cancer conducted during the last 15 years have failed to show marked improvement in median survival, suggesting that the selected approaches were not sufficient for several reasons, according to Heeschen. In recent years, researchers have identified cancer stem cells which, as opposed to the cancer cells that make up the bulk of the tumor, are a small subset of cells that are resistant to .

"Therefore, efficiently targeting these cells will be crucial for achieving higher cure rates in patients with pancreatic cancer," he said. "Our newly emerging data now indicate that metformin, a widely used and well-tolerated drug for the treatment of diabetes, is capable of efficiently eliminating these cells."

Specifically, the researchers found that metformin-pretreated cancer stem cells were particularly sensitive to alterations to their metabolism through the activation of . In fact, metformin treatment resulted in the death of cancer stem cells. In contrast, treatment of more differentiated with metformin only arrested the cells' growth.

"As the cancer stem cells represent the root of pancreatic cancer, their extinction by reprogramming their metabolism with metformin in combination with the stalling of the proliferation of more differentiated cells should result in tumor regression and long-term, progression-free survival," Heeschen said.

The researchers generated data to support this idea when they treated immunocompromised mice implanted with a diverse set of patient-derived tumors with a combination of metformin and gemcitabine, the standard chemotherapeutic treatment for pancreatic cancer. They found that the treatment resulted in reduced tumor burden and the prevention of relapse as compared with treatment with either drug alone.

"Intriguingly, in all tumors treated with metformin to date, of disease was efficiently prevented and there were no noticeable adverse effects," Heeschen said.

He believes that testing metformin in pancreatic cancer is ready for clinical trials. The pancreatic research team is currently awaiting results of a study that tested metformin as a maintenance treatment in patients with advanced pancreatic cancer. Although the rationale for this study was based on retrospective data, Heeschen said given these new results he hopes that this treatment strategy would be highly efficacious.

"Pending the results of this study, an important aspect for the future will be to investigate if all patients respond to metformin or whether some patients, due to distinct genetic alterations, may not respond to this metabolic reprogramming," he said.

Explore further: Embryonic signal drives pancreatic cancer and offers a way to kill it

More information:

Abstract

Metformin targets human pancreatic cancer stem cells in preclinical mouse models. Enza Lonardo, Michele Cioffi, Yolanda Sanchez, Jorge Dorado, Christopher Heeschen. Spanish National Cancer Research Centre, Madrid, Madrid, Spain.

Pancreatic ductal adenocarcinomas contain a subset of exclusively tumorigenic cancer stem cells (CSCs), which are capable of repopulating the entire heterogeneous populations of cancer cells in the tumor and, even more importantly, are highly resistant to standard chemotherapy. Therefore, the identification of drugs that are capable of selectively targeting CSCs is urgently needed. Here, we demonstrate that low dose metformin, a widely used anti-diabetic drug with an exceptional safety profile, selectively targets freshly isolated human pancreatic CSCs. Specifically, metformin pretreated sphere-derived CSCs showed strong activation of AMPK and loss of expression of pluripotency-associated genes and CSC-associated surface markers. Consecutively, the ability of pretreated CSCs to clonally expand in vitro and in vivo was virtually abrogated, while non-CSCs remained mostly unaffected by metformin treatment. Importantly, induction of energetic crisis resulting in enhanced apoptosis was restricted to p53-deficient CSCs, while p53 wild-type CSCs were resistant to the effects of metformin. Intriguingly, the combination of metformin with gemcitabine, the standard chemotherapeutic agent for pancreatic cancer, efficiently erased both CSCs and non-CSCs. Finally, in primary tissue xenograft mouse models this combination treatment effectively reduced tumor burden and prevented relapse as compared to either drug alone. Therefore, these data provide a strong experimental basis for further evaluating the combination of metformin and chemotherapeutic drugs to eventually improve the poor prognosis of patients with pancreatic cancer.

Related Stories

Embryonic signal drives pancreatic cancer and offers a way to kill it

November 3, 2011
Pancreatic cancer is a particularly challenging one to beat; it has a tendency to spread and harbors cancer stem cells that stubbornly resist conventional approaches to therapy. Now, researchers reporting in the November ...

Inhibiting Hedgehog signaling pathway may improve pancreatic cancer treatment

June 19, 2012
Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, ...

Metformin appeared to slow prostate cancer growth

April 1, 2012
The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Diabetes drug metformin shows promise in reducing risk of cancer

November 23, 2011
An inexpensive drug that treats Type-2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a newly published study by a Michigan State ...

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.